Middletown Life

Author: Cocrystal Pharma, Inc.

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

April 2, 2026
Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

March 31, 2026
First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

March 9, 2026
Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

February 19, 2026